and scored urine proteinuria, skin lesions and lymphadenopathy. At the end of the treatment interval, kidney, lung, spleen, skin, plasma and urine samples were collected and shipped to the coordinating study center for blinded analysis. All histopathological assessments were performed by an independent kidney pathology institute (RWTH Aachen, Germany) in a blinded fashion. The pre-set primary endpoint was urinary protein/creatinine ratio. Secondary endpoint analyses included plasma auto-antibodies levels, kidney histologic scores (activity and chronicity indices). Glomerular filtration rate and flow cytometry of splenocytes was performed on subgroups of mice at single centers.

**Results** A total of 56 mice were used, of which 13 in Madrid, 15 in Barcelona, 14 in Freiburg, and 14 in Munich. Mice were randomly assigned to baricitinib treatment (n=28) or vehicle (n=28). At treatment initiation, the average score of proteinuria (tested by sticks 0–4), skin lesion (0–4), and lymphadenopathy (0–6) for baricitinib treatment group were 1.38 ± 0.99, 0.95 ± 1.28, and 2.10 ± 1.80, respectively; above scores for vehicle group were 1.45 ± 1.10, 0.77 ± 1.02, and 1.81 ± 2.02, respectively. Data analysis is ongoing and will be presented at the conference.

**Conclusions** Preclinical double-blind, randomized, controlled, multicenter trials are a novel tool in preclinical drug testing that might help to predict the outcome of randomized clinical trials.

**P136** SLEDAI RESPONSE PREDICTION TO BELIMUMAB THERAPY BY BASELINE LEVELS OF BLYS, APRIL AND CD8+ EFFECTOR MEMORY T-CELLS

1. Francesca Regola, 2Silvia Piantoni, 1Laura Andreoli, 2Torsten Lowin, 1Paolo Airò, 1Francesco Franceschinì, 1Angela Tincani, 1Georg Pongratz. 1Rheumatology and Clinical Immunology, ASST Spedali Civili, University of Brescia, Brescia, Italy; 2Rheumatology and Hiller Research Center for Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany

**Background** Systemic Lupus Erythematosus (SLE) patients show high levels of Blys (B-lymphocyte stimulator) and other cytokines belonging to the tumor necrosis factor (TNF) superfamily1. Belimumab, a monoclonal antibody against Blys, mainly targets B-cells2, but a Blys-dependent T-cell activation pathway has been demonstrated3. Clinical studies showed that anti-DNA antibodies and complement levels at baseline are predictors of response to Belimumab. Our study aims at identifying other biomarkers as response predictors.

**Methods** Twenty-one SLE patients received Belimumab. Biomarkers belonging to the TNF superfamily (Blys, APRIL, sBCMA, sCD40L, sSTACI, TWEAK) were tested by ELISA in all patients and lymphocyte immunophenotyping was performed by flow cytometry in ten subjects at baseline and every six months. SLE-disease activity was assessed by SLEDAI-2K score.

**Results** Blys and APRIL baseline serum levels and the number of CD3+CD8+ effector memory T-cells were correlated positively with SLEDAI-2K improvement after 12 months of treatment (Pearson correlation=0.535 (p=0.015), 0.504 (p=0.023) and 0.654 (p=0.040)). After backwards exclusion from linear regression analysis including SLEDAI-2K, effector T-cell relative number and Blys or APRIL at baseline, only APRIL remained as significant independent predictor of SLEDAI-2K improvement after 12 months (adjusted R square=0.649; p=0.025). After comparing TNF-family members levels and SLEDAI-2K at baseline, only Blys showed the best predictive value (adjusted R 0.564, p<0.001).

**Conclusions** In our cohort of SLE patients, baseline level of APRIL together with percentage of CD3+CD8+ effector memory T-cells, or Blys serum level alone resulted as best predictors of response to Belimumab. Considering that immunophenotyping is rarely done in clinical practice, Blys baseline serum levels alone could be used routinely as a good predictor of response, as suggested by post-hoc analyses of the BLISS study.

**REFERENCES**